Compare Natera Inc. Common Stock (NTRA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Prospect Capital Corporation — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Prospect Capital Corporation trades at $1.58 (market cap $891.47M). The key difference: Natera Inc. Common Stock is far larger — about 64× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 25.15% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Prospect Capital Corporation for 78 Days on average.
| NTRA | PSEC | |
|---|---|---|
Market Cap | $57.03B | $891.47M |
Volume | 1,131,157 | 4,809,352 |
Sector | Health | Financials |
52-Week High | $425.64 | $3.05 |
52-Week Low | $179.42 | $1.60 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $2.65B |
Dividend Yield | — | 25.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PSEC trades at $1.60, down 7.51% with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly earnings have consistently beaten expectations, though the company maintains a modest 25% analyst buy rating amid ongoing dividend distributions of $0.04 monthly.
Outlook remains cautious due to negative cash flow and volatile revenue patterns. The 18%+ dividend yield attracts income investors but carries sustainability risks given declining NAV and portfolio contraction. Analyst consensus leans neutral with 55% hold ratings, reflecting concerns about long-term performance stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
